PURA and PAOG Confirm CBD IP Deal Schedule To Close Friday


Sandusky, OH, Dec. 01, 2021 (GLOBE NEWSWIRE) — Puration, Inc. (OTC Pink: PURA) and PAO Group, Inc. (OTC Pink: PAOG) today confirmed the companies have finalized terms for PAOG to acquire an exclusive license to a patented cannabis extraction process from PURA that will expand the PAOG’s existing CBD intellectual property.

Last year, PAOG acquired intellectual property derived through research into CBD extracted in association with a patented extraction method (U.S. Patent No. 9,199,960).  Now the company will acquire a license to the patent itself from PURA.

PAOG is developing both pharmaceutical and nutraceutical treatments for humans based on this intellectual property.

PURA has updated its business model over the course of the last year and is now focusing on the development of a hemp business cooperative under the brand name Farmersville Hemp.  PURA has recently detailed its new business model and three anticipated sources of revenue.  PURA has provided an initial, estimated $1 million forecast for 2022 and highlighted how its “partnership” revenue stream may contribute to a substantially exceeding the initial estimated forecast:

PURA Highlights Dark Horse Potential To Substantially Exceed $1M Revenue Forecast

The acquisition is expected to close this Friday, on December 3rd.

For more information on Puration, visit http://www.purationinc.com

Learn more about PAOG at www.paogroupinc.com.

Disclaimer:

This News Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause our actual results, performance or achievements, or industry results, to differ materially from any these statements. You are cautioned not to place undue reliance on any those forward-looking statements. Except as otherwise required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements after the date of this news release. None of such forward-looking statements should be regarded as a representation by us or any other person that the objectives and plans set forth in this News Release will be achieved or be executed.

For More Information, Contact:

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350

Jim DiPrima
888-272-6472
info@pao.group

Previous RAMM Pharma Corp. Welcomes Proposed Legalization of
Next Hofseth Biocare ASA: HBC INGREDIENTS SUCCESSFULLY RECEIVE